25th week of 2012 patent applcation highlights part 46 |
Patent application number | Title | Published |
20120156152 | SOFT SOLID ANTIPERSPIRANT COMPOSITIONS - A soft solid antiperspirant composition having reduced white marks, the composition comprising:
| 2012-06-21 |
20120156153 | Naturally Derived, Polymeric Hair Fixative Systems With Pullulan, And Mascara Compositions Comprising The Same - A naturally-derived, polymeric hair fixative system that is suitable for use in commercially acceptable mascara compositions. The hair fixative system comprises a natural, polymeric film forming system that comprises | 2012-06-21 |
20120156154 | Preservative and Embalming Method and System - Unique methods for preparing and producing non-toxic, liquid customized preservative substance formulations that may be used as embalming, sterilizing, disinfectant, preservative, mold destroying and fungus extermination solutions. These substances can: (a) safely resist or retard natural destructive processes; (b) save or keep things from decaying, decomposition, deterioration, spoiling, putrefication or fermentation; (c) continually prevent or inhibit unwanted microbial growth; and, (d) be used as embalming medical devices to significantly retard the carious destructive processes of nature with anti-microbial properties. These formulations forestall, prevent and inhibit undesirable chemical/biological changes, microbial/bacterial actions, plus retard decomposition or other negative changes. The formulations are comprised of ultra-fine minute nano-sized colloidal silver particles in pure distilled water resulting in stable suspended preparations. The formulations can be used as medical devices suitable for replacing toxic chemicals, disinfectants and preservatives. | 2012-06-21 |
20120156155 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156156 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156157 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156158 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156159 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156160 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156161 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156162 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2012-06-21 |
20120156163 | METHODS OF DECREASING SEBUM PRODUCTION IN THE SKIN - Provided herein are methods of using gaseous nitric oxide and/or at least one nitric oxide source to or decrease sebum production in the skin of a subject. In some embodiments, the nitric oxide source includes small molecule and/or macromolecular NO-releasing compounds. | 2012-06-21 |
20120156164 | IN SITU-FORMING HYDROGEL FOR TISSUE ADHESIVES AND BIOMEDICAL USE THEREOF - Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc. | 2012-06-21 |
20120156165 | SUSTAINED RELEASE PHEROMONE PREPARATION TARGETING INSECT PEST HAVING CARBOXYLIC ACID AS PHEROMONE SUBSTANCE - Targeting an insect pest having a carboxylic acid compound as a pheromone substance, provided is a sustained release pheromone preparation enabling a high amount of pheromone to be released during the control period. More specifically, provided is a sustained release pheromone preparation, comprising: a carboxylic acid compound to be released, and an ethylene-vinyl acetate copolymer membrane through which the carboxylic acid compound can permeate, wherein the preparation is targeted for an insect pest having the carboxylic acid compound as a pheromone substance. | 2012-06-21 |
20120156166 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 2012-06-21 |
20120156167 | ENHANCIN GENE BEL1 FROM BACILLUS THURINGIENSIS AND ITS USE IN BIOLOGICAL INSECTICIDE - The isolation, cloning of an enhancin gene bel1 from | 2012-06-21 |
20120156168 | VIRUSES FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS - Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent. | 2012-06-21 |
20120156169 | RECOMBINANT MYCOBACTERIUM STRAIN EXPRESSING A MYCOBACTERIAL FAP PROTEIN UNDER THE CONTROL OF A PROMOTER ACTIVE UNDER HYPOXIA AND ITS APPLICATION FOR CANCER THERAPY - The invention relates to a recombinant vector comprising a mycobacterial FAP protein coding sequence under the transcriptional control of a promoter active under hypoxia conditions and its use for the prevention and the treatment of epithelial tumors. | 2012-06-21 |
20120156170 | DRUG COMPOSITION FOR ANGIOGENESIS THERAPY - The present invention relates to: drug compositions of angiogenesis therapy that contains gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I | 2012-06-21 |
20120156171 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF SENSITIVE OR DRY SKIN - The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the preventional and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle. | 2012-06-21 |
20120156172 | NEW LACTIC ACID BACTERIA HAVING ITS INHIBITORY EFFECT ON AVIAN INFLUENZA VIRUS INFECTION AND COMPOSITION CONTAINING THE SAME - The present invention relates to a new microorganism | 2012-06-21 |
20120156173 | FUSARIUM AND OTHER PATHOGENIC FUNGI AND MYCOTOXIN BIOCONTROL - The present disclosure relates to a novel ascomyceteous fungus, | 2012-06-21 |
20120156174 | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against | 2012-06-21 |
20120156175 | COMPOSITION FOR INDUCING MIGRATION OF NEURAL STEM CELLS CONTAINING PERIOSTIN AS EFFECTIVE INGREDIENT - A novel use of periostin, and more particularly a composition for inducing the migration of neural stem cells, which contains periostin or a periostin-secreting cell as an active ingredient, based on the discovery of a novel function of periostin that induces the migration of neural stem cells. Periostin induces the migration of neural stem cells, and thus the composition for inducing the migration of neural stem cells, which contains periostin or periostin-secreting cells as an active ingredient, can be used in various applications based on neural stem cells. A pharmaceutical composition containing suicide gene-expressing neural stem cells and periostin allows the neural stem cells to effectively migrate to tumor tissues, and thus can be used as a cell therapeutic agent for treating cancer. Also, the pharmaceutical composition containing neural stem cells and periostin has improved effects on the stimulation of regeneration of nerve cells and the treatment of neural diseases. | 2012-06-21 |
20120156176 | THERMORESPONSIVE, BIODEGRADABLE, ELASTOMERIC MATERIAL AND USES THEREFOR - Provided are novel biocompatible copolymers and compositions comprising the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers. | 2012-06-21 |
20120156177 | METHODS AND DEVICES FOR HARVESTING AND PROCESSING CONNECTIVE TISSUE PRECURSOR CELLS FROM AUTOLOGOUS FAT - Methods and devices are disclosed for repairing injured, infected, or otherwise damaged connective tissues. Such repairs use injectable combinations of: (i) stromal precursor cells, which can be obtained from a patient via liposuction, and which can mature rapidly into muscle, ligament, tendon, or other types of connective tissue cells that are needed at a repair site; and (ii) platelets, which will accelerate and promote a repair process, and which can be obtained from the patient's blood. When mixed together, stromal precursor cells and platelet cells will act synergistically, to generate new tissue which can replace or repair damaged tissue. Devices and methods are disclosed for processing an already-centrifuged layer of “spun fat”, obtained from a liposuction extract, to remove unhelpful materials and concentrate the stromal precursor cells, before the stromal cells are mixed with platelet cells for injection into a patient. | 2012-06-21 |
20120156178 | TREATMENT OF PEYRONIES DISEASE - The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios. | 2012-06-21 |
20120156179 | METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS - The present invention relates to a method for inducing proliferation of functionally differentiated somatic cells comprising a step of activating expression of a Myc family gene and a KIf family gene in said cells or contacting said cells with a Myc family protein and a KIf family protein. | 2012-06-21 |
20120156180 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRABBE AND OTHER NEURODEGENERATIVE DISEASES - Provided are compositions and methods for the treatment of Krabbe and other neurodegenerative diseases, including storage diseases such as GM1 gangliosidosis, Niemann-Pick disease, Tay-Sachs disease, Sandhoff disease, metachromatic leukodystrophy, Canavan disease, Pelizaeus-Merzbacher disease, and storage conditions facilitated by aging of lysosomal functions, which are associated with psychosine (and/or other storage material)-mediated axonal degeneration. Compositions and methods employ (1) one or more inhibitor of a phos-photransferase activity of one or more kinase(s) such as, for example, CDK5, P38, jnk, src, CK2, PKC, GSK3α and β; (2) one or more inhibitor of a phosphotransferase activity of one or more phosphatase(s) such as, for example, the Ser/Thr protein phosphatase PP1 and Tyr protein phosphatase PP2; one or more inhibitor of a caspase/calpain activity of one or more caspases such as caspase 3 and calpains such as calpain 1 and 2; and (4) one or more inhibitor of a sodium/calcium exchange protein such as, for example, NCX1. Inhibitors include small molecules, including the GSK3β inhibitor L803 and the NCX1 inhibitor flecainide, and siRNA molecules that downmodulate cellular levels of one or more mRNA, including siRNA that are capable of downmodulating the cellular expression of PP1. Inhibitors disclosed can cross the blood-brain barrier and, thus, are available to the central nervous system (CNS) and effective in reducing psychosine-mediated axonal degeneration. | 2012-06-21 |
20120156181 | THERAPEUTIC AGENT FOR LIVER-RELATED DISEASES - The present invention relates to a therapeutic agent for liver-related diseases, comprising adipose tissue-derived multilineage progenitor cells; and others. | 2012-06-21 |
20120156182 | Autogenic Living Scaffolds and Living Tissue Matrices: Methods and Uses Thereof - The present invention is drawn to a 3-dimensional cell-produced scaffold construct comprising cells and the extracellular matrix that has been produced and arranged by these cells. | 2012-06-21 |
20120156183 | SORCS1-LIKE AGENT FOR USE IN THE TREATMENT OF INSULIN RESISTANCE AND DISEASES RELATED THERETO - The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for use in the treatment of insulin resistance. | 2012-06-21 |
20120156184 | METHODS AND MATERIALS FOR TREATING BURN INJURIES - This document provides methods and materials involved in treating burn injuries. For example, methods and materials for using skin grafts (e.g., autologous skin grafts) treated with an autologous platelet concentrate and autologous thrombin to treat burn injuries (e.g., deep skin burn injuries) are provided. | 2012-06-21 |
20120156185 | NUTRITIONAL COMPOSITIONS COMPRISING CITRUS FIBERS - The present invention provide edible compositions comprising soluble and insoluble dietary fibers at a ratio of about 1:1 ratio, having a palatable taste, useful for reducing the serum lipid content in a mammal, and further for reducing the blood glucose level, enhancing the feeling of satiety and keeping a desired body weight. | 2012-06-21 |
20120156186 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described. | 2012-06-21 |
20120156187 | METHODS AND COMPOSITIONS FOR MODULATION OF BLOOD-NEURAL BARRIER - Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist. | 2012-06-21 |
20120156189 | SKIN COSMESIS TREATMENT WITH CLOSTRIDIA NEUROTOXINS - Methods of using clostridial toxins and other biological agents to treat skin cosmesis in humans is provided. The disclosed methods provide beneficial effects in humans. | 2012-06-21 |
20120156190 | Influenza Prevention And Treatment Composition - A composition for influenza prevention and treatment includes bio-transformed soy and St. John's wort. | 2012-06-21 |
20120156191 | ANTI-JAM-A ANTIBODIES - The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening. | 2012-06-21 |
20120156192 | Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 2012-06-21 |
20120156193 | Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 2012-06-21 |
20120156194 | DIAGNOSIS AND TREATMENTS RELATING TO TH2 INHIBITION - Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors. | 2012-06-21 |
20120156195 | Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus - This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection. | 2012-06-21 |
20120156196 | ANTI-ANTHRAX ANTIBODY, FORMULATIONS THEREOF, AND METHODS OF USE - The present invention provides an antibody which binds to | 2012-06-21 |
20120156197 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS - Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone. | 2012-06-21 |
20120156198 | Antibodies against IL-18R1 and uses thereof - The invention provides anti-IL-18R1 antibodies and methods of using the same. | 2012-06-21 |
20120156199 | USE OF PICOPLATIN TO TREAT COLORECTAL CANCER - The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. | 2012-06-21 |
20120156200 | METHOD OF TREATING CANCER - Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923. | 2012-06-21 |
20120156201 | HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6 METHODS AND USES THEREOF - The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods. | 2012-06-21 |
20120156202 | AGE RELATED MACULAR DEGENERATION TREATMENT - A method for treating age related macular degeneration (AMD) using an insulin preparation applied topically to the conjunctival sac of the affected eye. Another aspect of this invention is using antiangiogenic adjuvant therapeutic agents such as bevacizumab, ranibizumab, pegaptanib, etanercept, instilled in to the afflicted eye conjunctival sac with insulin to prevent further formation of new blood vessels, and shrink the existing pathologically formed blood vessels and reduce the edema in wet AMD. This method incorporates putting the patients on low fat diet, aerobic exercise, ketamine-a NMDA blocker, reducing the blood cholesterol using adjuvant therapeutic agents selected from Statins, that are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A, (i.e. HMG-Co A) reductase which in turn reduce drusen formation that leads to AMD, combined with insulin ophthalmic drops. | 2012-06-21 |
20120156203 | NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 2012-06-21 |
20120156204 | METHODS FOR INCREASING ADIPONECTIN - In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations. | 2012-06-21 |
20120156205 | MONOCLONAL ANTIBODIES TO PROGASTRIN - The present invention provides progastrin-binding molecules that are useful therapeutically for passive immunization against progastrin in gastrin-promoted diseases or conditions. The progastrin-binding molecules are specific for progastrin but do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly) or glycine-extended gastrin-34(G34-Gly). The progastrin-binding molecules include monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin. | 2012-06-21 |
20120156206 | C-MET ANTIBODY COMBINATIONS - The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein. | 2012-06-21 |
20120156207 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 2012-06-21 |
20120156208 | THERAPEUTIC USES OF INHIBITORS OF RTP801 - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein. | 2012-06-21 |
20120156209 | ANTI-IL-TIF ANTIBODIES AND METHODS OF USE - The present invention relates to ZCYTO18 polynucleotide and polypeptide molecules. The ZCYTO18 is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2012-06-21 |
20120156210 | METHODS OF TREATMENT USING ANTI-IL-22RA ANTIBODIES - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners. | 2012-06-21 |
20120156211 | PORPHYROMONAS GINGIVALIS POLYPEPTIDES - Provided herein are compositions and methods for eliciting an immune response against | 2012-06-21 |
20120156212 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA - The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof. | 2012-06-21 |
20120156213 | METHOD FOR TREATING TH17 INFLAMMATORY DISEASE THROUGH INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS AND PHARMACEUTICAL COMPOSITION THEREFOR - The present application relates to a method for treating or preventing Th17 inflammatory disease mediated with IL-6 or IL-17 by administration of medication which inhibits vascular endothelial growth factor receptors, and a pharmaceutical composition therefor. | 2012-06-21 |
20120156214 | SOLUBLE LYMPHOTOXIN-BETA RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES - Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. | 2012-06-21 |
20120156215 | Phage-GnRH Constructs, Their Mimics, Antigenic Compositions, and Sequences for Immunocontraception of Animals and Other Applications - Disclosed are recombinant bacteriophage constructs and related heterologous peptide sequences for contraception in animals. The disclosed recombinant phage constructs bind to antibodies against gonadotropin releasing hormone (GnRH) and can be administered to an animal to generate an immune response against GnRH, including generating anti-GnRH antibodies. The disclosed recombinant phage may comprise an amino acid sequence of gonadotropin releasing hormone (GnRH), epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against GnRH including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein. | 2012-06-21 |
20120156216 | Methods and Compositions for Treatment of Tumor Metastasis - The various embodiments of the present invention are directed to methods and compositions for treatment, inhibition or reduction of metastasis in cancers. In particular, the invention is related to compositions and methods affecting connective tissue growth factor (CTGF). An aspect of the present invention comprises a method for interfering with the activity of connective tissue growth factor, comprising, administering to a subject an effective amount of a composition that inhibits production of or activity of connective tissue growth factor (CTGF), wherein the composition interferes with the activity of CTGF or prevents the transcription of CTGF genes or translation of CTGF mRNA. For example, the composition can comprises at least one HMG-CoA reductase inhibitor compound, such as a statin. | 2012-06-21 |
20120156217 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided. | 2012-06-21 |
20120156218 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38 | 2012-06-21 |
20120156219 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF - The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. | 2012-06-21 |
20120156220 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 2012-06-21 |
20120156221 | Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders - The invention relates to compounds which activate the BASIGIN signaling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders. | 2012-06-21 |
20120156222 | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to a purified antibody that specifically binds an α-synuclein protofibril. | 2012-06-21 |
20120156223 | Method for Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens - Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided. | 2012-06-21 |
20120156224 | MODULATION OF TIM RECEPTOR ACTIVITY IN COMBINATION WITH CYTOREDUCTIVE THERAPY - A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1. | 2012-06-21 |
20120156225 | METHOD OF THERAPY - Numerous diseases have been linked to the production of regulator cells. The present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also relates to methods of determining when a therapy to treat a disease characterized by the production of regulator cells should be administered to a patient. | 2012-06-21 |
20120156226 | Marker Differentially Expressed in Cancer Stem Cells and Methods of Using Same - The present invention pertains to methods and agents that target nanog expression or activity for treating or preventing cancer. Alternative methods involve diagnosing cancer stage or type by identifying presence of cancer cells expressing nanog. Other embodiments relate to methods of identifying agents that modulate nanog. | 2012-06-21 |
20120156227 | PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT - A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination | 2012-06-21 |
20120156228 | Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair - The invention features methods, kits, and compositions for generating new hair follicles and growing hair on a subject. | 2012-06-21 |
20120156229 | QUICKLY SOLUBLE ORAL FILM DOSAGE CONTAINING STEVIOSIDES AS A UNPLEASANT TASTE MASKING AGENT - Disclosed is a quickly soluble oral film dosage for masking a nasty taste, in particular, a quickly soluble oral film dosage comprising a stevioside based sweetener and a high potency sweetener in a ratio by weight (w/w) of 1:3 to 3:1, which may efficiently mask a bitter or nasty taste of a medicine and may be quickly dissolved in a mouth without water, thereby improving an aftertaste thereof thus enhancing dosage acceptability of a patient. | 2012-06-21 |
20120156230 | TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an injury to the central nervous system, such as a spinal cord injury or a traumatic brain injury, using placental stem cells and placental multipotent stem cells described herein, and populations of such placental cells. | 2012-06-21 |
20120156231 | FOXM1 PEPTIDES AND VACCINES CONTAINING THE SAME - The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor. | 2012-06-21 |
20120156232 | CANCER VACCINES AND VACCINATION METHODS - Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein. | 2012-06-21 |
20120156233 | VACCINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION - The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells. | 2012-06-21 |
20120156234 | MEANS FOR TREATING SYNUCLEINOPATHIES - The present invention relates to peptides or polypeptides for producing medicaments for preventing and/or treating synucleinopathies. | 2012-06-21 |
20120156235 | Antibodies Against And Methods For Producing Vaccines For Respiratory Syncytial Virus - The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. | 2012-06-21 |
20120156236 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2012-06-21 |
20120156237 | Novel Antitoxin and Vaccine Platform Based on Nodavirus VLPS - Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided. | 2012-06-21 |
20120156238 | HERPES VIRUS BACKBONE FOR VIRAL VACCINE AND VACCINE BASED THEREON - A recombinant deoxyribonucleic acid comprising a human herpes simplex virus (HSV) deoxyribonucleic acid (DNA) having a heterologous DNA integrated therein wherein the heterologous DNA encodes a polypeptide comprising a RING-finger domain; a recombinant virus comprising such, a viral vaccine and methods of immunization are provided. | 2012-06-21 |
20120156239 | OPTIMIZED VACCINES TO PROVIDE PROTECTION AGAINST EBOLA AND OTHER VIRUSES - The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same. | 2012-06-21 |
20120156240 | METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM - The present disclosure provides methods for preparing vesicles. In some embodiments, the methods involve providing a molten mixture of vesicle forming lipids and then adding the molten mixture to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. In other embodiments, the methods involve providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by melting vesicle-forming lipids to produce a molten lipid mixture and then lyophilizing the molten lipid mixture. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container. | 2012-06-21 |
20120156241 | RESCUE OF INFLUENZA VIRUS - The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. In one embodiment, the invention provides a nucleic acid comprising an influenza gene segment and a bacteriophage polymerase promoter or a complementary strand of said nucleic acid, and a cell comprising such a nucleic acid capable of producing desired influenza virus. In another embodiment, the invention provides a composition comprising a cell or material derived from a cell according to the invention and a virus or material derived from a viral particle according to the invention. | 2012-06-21 |
20120156242 | An Antigenic Peptide Derived From Influenza Virus And A Method For Selecting Anti-Influenza Virus Antibody - Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP). | 2012-06-21 |
20120156243 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 2012-06-21 |
20120156244 | Nasal Compositions and Uses Thereof - Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions. | 2012-06-21 |
20120156245 | Methods for the Prevention of Malaria - This application relates to preventing malaria by administering a vaccine. More particularly, this invention relates to a vaccine against malaria infection compromising the administration of attenuated sporozoites to a human or animal. | 2012-06-21 |
20120156246 | REPROGRAMMING CANCER CELLS - The present application describes a method of treating a patient with cancer or at risk of developing cancer with at least one regulatory element that induces differentiation of cells. | 2012-06-21 |
20120156247 | BIOCOMPOSITION STIMULANT OF THE IMMUNE SYSTEM, ANTI-TUMOUR AND ANTI-HIV - Provided is a herbal composition of plants obtained from non-domestic wild sources by means of meristems and the extracts thereof obtained using improved processes, in which the extracts and the active principles thereof generate a synergism demonstrating anti-inflammatory, antiviral nutritional supplement, immune system simulating, prostatic health promoting and supporting properties for improving quality of life with a wide range of benefits in individuals with chronic terminal diseases. | 2012-06-21 |
20120156248 | AUGMENTATION OF TITER FOR VACCINATION IN ANIMALS - The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine. | 2012-06-21 |
20120156249 | GENETICALLY MODIFIED ORGANISM FOR THE PRODUCTION OF LIPIDS - The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-CoA: sterol acyltransferase/sterol O-acyltransferase (EC 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol O-acyltranferase (EC 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (EC 2.3.1.158) and/or acyl CoA-wax alcohol acyltransferase (EC 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism. | 2012-06-21 |
20120156250 | COMPOSITIONS AND METHODS FOR CARDIAC THERAPY - Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue. | 2012-06-21 |
20120156251 | CATIONIC OIL-IN-WATER EMULSIONS - This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines. | 2012-06-21 |
20120156252 | METHOD OF PRODUCING MICROBEADS - A method for producing microbeads comprising an active component encapsulated within a gelled polymer matrix comprises the steps of providing a suspension of denatured whey protein and an active component, treating the suspension to generate microbeads, and immediately curing the microbeads by acidification. The microbeads are discrete droplets of gelled whey protein having an average diameter in the micron range (for example, from 80 to 500 microns) and which, suitably have a generally spherical shape. The microbeads are capable of surviving passage through the stomach, and delivering the encapsulated active agent in the instestine. Ex-vivo and in-vivo data shows that active agent encapsulated within microbeads retains its functionality upon delivery to the intestine, and that coating of the microcapsules allows targeted delivery of the active agent to the distal part of the intestine. | 2012-06-21 |